COST/UTILITY ANALYSIS (CUA) OF VALSARTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN ITALY BASED ON THE VAL-HEFT TRIAL

被引：0
|
作者：
Pradelli, L. [1 ]
Iannazzo, S. [1 ]
Zaniolo, O. [1 ]
机构：
[1] AdRes Srl, Turin, Italy
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66370-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A403 / A404
页数：2
相关论文
共 50 条
  • [41] Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
    McMurray, JJV
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2001, 2 (02) : 89 - 92
  • [42] High sensitive troponin T is a strong predictor of outcomes in patients with chronic heart failure - A study from the Val-HeFT trial
    Latini, R
    Masson, S
    Anand, IS
    Vago, T
    Barlera, S
    Hallermayer, K
    Maggioni, AP
    Tognoni, G
    Cohn, JN
    CIRCULATION, 2005, 112 (17) : U567 - U567
  • [43] Non-ischemic congestive heart failure without renin-angiotensin-aldosterone and adrenergic systems activation in South African Blacks in Val-HeFT
    Maggioni, AP
    Anand, I
    Masson, S
    Naidoo, DP
    Latini, R
    Judd, DL
    Spormann, DP
    Glazer, R
    Tognoni, G
    Cohn, JN
    CIRCULATION, 2000, 102 (18) : 536 - 536
  • [44] The Cost Effectiveness and Cost Utility of Valsartan in Chronic Heart Failure Therapy in Italy A Probabilistic Markov Model
    Pradelli, Lorenzo
    Iannazzo, Sergio
    Zaniolo, Orietta
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2009, 9 (06) : 383 - 392
  • [45] Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: Data from the Val-HeFT heart failure trial
    Staszewsky, Lidia
    Wong, Maylene
    Masson, Serge
    Barlera, Simona
    Carretta, Elisa
    Maggioni, Aldo P.
    Anand, Inder S.
    Cohn, Jay N.
    Tognoni, Gianni
    Latini, Roberto
    JOURNAL OF CARDIAC FAILURE, 2007, 13 (10) : 797 - 804
  • [46] Are statins of clinical benefit in patients with established systolic chronic heart failure? A retrospective analysis of 5010 patients enrolled in Val-HeFT
    Krum, H
    Carretta, E
    Latini, R
    Maggioni, A
    Masson, S
    CIRCULATION, 2004, 110 (17) : 680 - 680
  • [47] Statins in symptomatic chronic systolic heart failure. A post-hoc analysis of 5010 patients enrolled in Val-HeFT
    Latini, R
    Maggioni, AP
    Anand, IS
    Masson, S
    Carretta, E
    Glazer, R
    Krum, H
    Cohn, JN
    EUROPEAN HEART JOURNAL, 2004, 25 : 246 - 246
  • [48] Direct comparison of B-Type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The valsartan heart failure (Val-HeFT) data
    Masson, Serge
    Latini, Roberto
    Anand, Inder S.
    Vago, Tarcisio
    Angelici, Laura
    Barlera, Simona
    Missov, Emil D.
    Clerico, Aldo
    Tognoni, Gianni
    Cohn, Jay N.
    CLINICAL CHEMISTRY, 2006, 52 (08) : 1528 - 1538
  • [49] Valsartan reduces morbidity in heart failure patients receiving background angiotensin-converting enzyme inhibitors but not receiving beta-blockers: results from Val-HeFT
    Krum, H
    Maggioni, A
    Farsang, C
    EUROPEAN HEART JOURNAL, 2002, 23 : 649 - 649
  • [50] A retrospective analysis of major markers of heart failure severity in patients receiving both ACE inhibitors and beta-blockers in Val-HeFT
    Anand, IS
    Glazer, R
    Chiang, T
    Latini, R
    Maggioni, AP
    Hester, A
    Aknay, N
    Carson, P
    Tognoni, G
    Cohn, JN
    CIRCULATION, 2003, 108 (17) : 445 - 446
12345